Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970–1979 1974: FDA approves doxorubicin, a vital part of combination chemotherapy.

Slides:

Advertisements

Similar presentations

The Basics of Cancer Roswell Park Cancer Institute Grades 5-8.

Advertisements

Major Cancer Milestones

Progress Against Breast Cancer

Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.

Progress Against Lung Cancer. 1970–1979 Progress Against Lung Cancer 1970–1979 Mid-1970s: Chemotherapy combinations prove effective in small cell lung.

Progress Against Stomach Cancer. 1980–1989 Progress Against Stomach Cancer 1980– : Combination chemotherapy improves outcomes for advanced stomach.

Progress Against Bladder Cancer. Pre-1970 Progress Against Bladder Cancer Pre : Tool offers view inside bladder for first time.

Progress Against Ovarian Cancer. 1970–1979 Progress Against Ovarian Cancer 1970– : First effective combination chemotherapy regimen for ovarian.

Progress Against Testicular Cancer. 1970–1979 Progress Against Testicular Cancer 1970– : Two new drugs produce first complete remissions in advanced.

Progress Against Cervical Cancer. 1980–1989 Progress Against Cervical Cancer 1980– –1984: HPV virus is discovered to cause cervical cancer.

Progress Against Head and Neck Cancer. 1970–1979.

Progress Against Melanoma. 1970–1979 Progress Against Melanoma 1970– : Hereditary syndrome linked to increased melanoma risk.

Progress Against Leukemia. 1970–1979 Progress Against Leukemia 1970– : FDA approves doxorubicin.

Progress Against Kidney Cancer. 1970–1979 Progress Against Kidney Cancer 1970– : Removing just part of the cancerous kidney is proven safe and.

Progress Against Pancreatic Cancer. 1970–1979 Progress Against Pancreatic Cancer 1970– s: Tobacco use found to cause pancreatic cancer.

Progress Against Liver Cancer. 1970–1979 Progress Against Liver Cancer 1970– : First study finds chemotherapy effective for liver cancer.

Presenter Name(s) Issue date National Student.

Through the years… JUNIATA COLLEGE FIELD HOCKEY. SeasonCoachRecord 1973Unknown Jo Reilly Alexa Fultz Alexa Fultz Nancy Harden-Latimore4-4-1.

From Delft into Almere Prof.dr.ir.Taeke M. de Jong.

Landings by Species Group and Year. Revenue by Species Group.

Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.

LEUKEMIA & LYMPHOMA SOCIETY TEAM IN TRAINING. THE LEUKEMIA & LYMPHOMA SOCIETY WORLDS LARGEST VOLUNTARY HEALTH ORGANIZATION DEDICATED TO FUNDING BLOOD.

Leukemia By Mary Chen and Genesis Pimentel

Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.

LEUKEMIA. What Is It? Leukemia is a type of cancer that starts in the tissue that forms blood.

By Taylor, Lanny, and Alex. What is it?  Leukemia is an abnormal rise in the number of white blood cells. The white blood cells crowd out other blood.

CANCER AND ADOLESCENTS Contemporary Health 2 Caroline Montagna Matt Lorup.

WITHOUT ANIMAL RESEARCH…  Polio would kill or cripple thousands of unvaccinated children and adults this year  Some of the 50 to 60 percent of newborns.

Case for Support. Blood Cancers More than 1 million North Americans are fighting blood cancers, the third leading cause of cancer deaths. Early detection.

Sami Sasala Brooke McVay Tiffany Vandiver

Cancer By: Erionne. What is Cancer Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you.

Treatment of Leukemias and Lymphomas December 2013.

Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.

DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.

بسم الله الرحمن الرحيم. Adult Hodgkin’s Lymphoma in the Eastern Part of Libya Dr. M.Mangoush, R. Nafo, S.Kardah, M.Letaiwish, S.Kardah, F.Bodabous, S.Ebkhatra.

Is there Hope for Children with Cancer? Yaritza Delgado.

LYMPHOMA Malignant transformation of cell in Lymphatic system There are about 600 Lymph Nodes in the body Spleen and gut also have lymphatic tissue.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.

ASH 2009: Community Perspectives on Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Moderator John Leonard, MD Professor of Medicine Weill Cornell.

By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.

Hematopoietic Stem Cell Transplantation (HSCT)

Bijoy Telivala, MD Advances in Immunotherapy Bijoy Telivala, MD

A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,

Campos M et al. Proc EHA 2013;Abstract B2009.

Non-Hodgkin’s Lymphoma

Campos M et al. Proc EHA 2013;Abstract B2009.

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.

Director Department of Pediatric Hematology & Oncology Delhi, INDIA.

Response to chemotherapy

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

by James O. Armitage, and Dan L. Longo

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

R-CHOP Stem Cell Transplantation for Follicular Lymphoma

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

by Michael F. Leahy, and J. Harvey Turner

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Zaja F et al. Proc ASH 2010;Abstract 966.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

by Lapo Alinari, and Kristie A. Blum

Presentation transcript:

Progress Against Lymphoma

1970–1979

Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy

Progress Against Lymphoma 1970– : New chemotherapy regimen boosts Hodgkin lymphoma cure rates to 70 percent 1975: Era of bone marrow transplantation begins – extending lives of many patients with leukemia and lymphoma

Progress Against Lymphoma 1970– : CHOP regimen boosts cure rates for non- Hodgkin lymphoma

Progress Against Lymphoma 1980–1989

Progress Against Lymphoma 1980– : Imaging tests begin replacing surgery for Hodgkin lymphoma staging

Progress Against Lymphoma 1980–1989 Late 1980s: Benzene established to cause blood cancers

Progress Against Lymphoma 1990–1999

Progress Against Lymphoma 1990– : Mantle cell lymphoma recognized as a subtype of non-Hodgkin lymphoma

Progress Against Lymphoma 1990– s: Research suggests a therapeutic vaccine for follicular lymphoma could be possible 1995: Lymphocyte transfusions re-induce leukemia remissions 1995: Bone marrow transplantation improves survival for relapsed non-Hodgkin lymphoma

Progress Against Lymphoma 1990– : FDA approves first-ever targeted cancer drug, rituximab 1997: Classification system established for non- Hodgkin lymphoma

Progress Against Lymphoma 1990– : New technique enables older patients to undergo life-saving stem cell transplants

Progress Against Lymphoma 2000–Present

Progress Against Lymphoma 2000–Present 2001: Scientists discover that common type of lymphoma is two distinct diseases

Progress Against Lymphoma 2000–Present 2002: Adding rituximab to ''CHOP'' chemotherapy boosts survival 2002: Radioimmunotherapy introduced to treat lymphoma

Progress Against Lymphoma 2000–Present 2005: Bortezomib shrinks tumors in mantle cell lymphoma

Progress Against Lymphoma 2000–Present 2007: PET scanning helps guide lymphoma treatment

Progress Against Lymphoma 2000–Present 2008: First drug approved specifically for T-cell lymphoma treatment

Progress Against Lymphoma Five-Year Survival Source: National Cancer Institute

Progress Against Lymphoma Mortality Source: National Cancer Institute

Progress Against Lymphoma New Cases Source: National Cancer Institute

Visit CancerProgress.Net for an interactive timeline of progress against a range of common cancers CancerProgress.Net is a project of the American Society of Clinical Oncology, which represents nearly 30,000 physicians who treat people with cancer and research new cures